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Abstract
Background: Lung cancer remains a leading cause of cancer death among both men and women
in the United States. Treatment modalities available for this malignancy are inadequate and thus
new drugs with improved pharmacological profiles and superior therapeutic indices are being
continually explored. Noscapinoids constitute an emerging class of anticancer agents that bind
tubulin but do not significantly alter the monomer/polymer ratio of tubulin. EM011, a rationally-
designed member of this class of non-toxic agents, is more potent than the lead molecule,
noscapine.
Results: Here we report that EM011 inhibited proliferation of a comprehensive panel of lung
cancer cells with IC50's ranging from 4-50 μM. In A549 human non-small cell lung cancer cells, the
antiproliferative activity was mediated through blockage of cell-cycle progression by induction of a
transient but robust mitotic arrest accompanied by activation of the spindle assembly checkpoint.
The mitotically-arrested A549 cells then override the activated mitotic checkpoint and aberrantly
exit mitosis without cytokinesis resulting in pseudo G1-like multinucleated cells that either
succumb directly to apoptosis or continue another round of the cell-cycle. The accumulated
enormous DNA perhaps acts as genotoxic stress to trigger cell death. EM011-induced apoptotic
cell death in A549 cells was associated with a decrease of the Bcl2/BAX ratio, activation of caspase-
3 and cleavage of PARP. Furthermore, EM011 induced downregulation of survivin expression over
time of treatment. Abrogation of survivin led to an increase of cell death whereas, overexpression
caused decreased apoptosis.
Conclusion: These in vitro data suggest that EM011 mediates antiproliferative and proapoptotic
activity in non-small cell A549 lung cancer cells by impeding cell-cycle progression and attenuating
antiapoptotic signaling circuitries (viz. Bcl2, survivin). The study provides evidence for the potential
usefulness of EM011 in chemotherapy of lung cancer.
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Lung cancer is a leading cause of death worldwide. Non-
small cell lung cancer (NSCLC) accounts for ~80-85% of
all cases of lung cancer, and ~45% of patients present with
stage IIIA/B disease [1]. Besides the metastatic nature of
this disease, drug resistance that emerges upon prolonged
treatment with particular drug/s has been responsible for
poor survival statistics, and the overall scenario empha-
sizes need for effective and well-tolerated treatment regi-
mens. Even with the best currently-available treatment,
lung cancer can only be cured at its earliest stage, and the
5-year survival rate is a low 5 percent. Although many tra-
ditional cytotoxics have been used as monotherapy in
NSCLC, including vindesine, docetaxel, carboplatin,
etoposide, ifosfamide, cyclophosphamide, vincristine,
mitomycin and cisplatin [2], these drugs produce only
small improvements, and several debilitating toxicities
significantly compromise the quality of life and decrease
survival. Thus, the need for development of more effective
therapeutic strategies for NSCLC that offer improved
pharmacological profiles and superior therapeutic indices
is crucial.
The mitotic spindle, a highly evolved elegant structure
that orchestrates faithful chromosome segregation during
cell division, is a pharmaceutically validated target for
anticancer therapy [3,4]. Since dynamic microtubules that
compose the mitotic spindle have a critical role in cell
division, various microtubule inhibitors have been devel-
oped as successful anticancer drugs. Two major classes of
microtubule-interfering agents are well recognized in the
clinic today. They comprise the taxanes (represented by
paclitaxel, docetaxel etc.) that overpolymerize and bundle
microtubules, and the vinca alkaloids (typified by vinblas-
tine, vincristine, vinflunine etc.) that depolymerize micro-
tubules. Several of these microtubule depolymerizing
agents have been widely employed for the treatment of
NSCLC [5,6]. However, due to the extreme effects of these
drugs on microtubules, critical physiological functions
that microtubules perform, such as intracellular transport,
are compromised (reviewed in [7]). In addition, these
microtubule inhibitors act on both proliferating and post-
mitotic cells and thus exhibit microtubule-dependent side
effects, including peripheral neuropathy [8,9].
Noscapinoids, an emerging class of microtubule-modu-
lating anticancer agents based upon the lead molecule,
noscapine apparently avoid the harsher effects of the cur-
rently-available antimicrotubule agents [10-19]. Noscap-
ine and its analogs do not alter the steady state polymer
levels of tubulin, instead dampen microtubule dynamics
just enough to perhaps activate the mitotic checkpoints to
halt mitosis without perturbing other vital microtubule
functions such as axonal transport [13,16]. This perhaps
might be the reason for lack of apparent toxicity upon
treatment with noscapine and its analogs [11,14-18].
Based upon anticancer activity and non-toxic attributes,
the parent molecule, noscapine, is already in Phase I/II
clinical trials.
The brominated noscapine analog, EM011, is more active
than the parent noscapine, as reported by the 60-cell line
anticancer screen conducted by the Developmental Ther-
apeutics Program (DTP) at the National Institutes of
Health [19]. EM011 retains the tubulin-binding capacity
and preserves the non-toxic attributes of noscapine [13-
15,17,18]. Earlier reports have shown that EM011 inhib-
ited growth of pgp- and MRP- overexpressing human lym-
phoma xenografts implanted in nude mice [14,17]. In this
study, we wished to evaluate whether or not EM011 that
shows potent in vitro and in vivo anticancer activity in sev-
eral cancer types, is useful for treating lung cancer. Our
results demonstrate that EM011 inhibited proliferation of
a variety of human lung cancer cells with an IC50 ranging
from 4-50 μM. A robust mitotic arrest through activation
of the spindle assembly checkpoint was observed upon
drug-treatment of A549 cells. Mitotically-arrested cells
then exited mitosis without cytokinesis in a phenomenon
called mitotic slippage into a pseudo G1-like interphase
state and subsequently activated apoptotic cell-death
pathways. However, a small percentage of these mitoti-
cally-slipped tetraploid cells entered another round of
cell-cycle and thus accumulated massive DNA amounts
that possibly trigger apoptosis due to genotoxic stress. Fur-
thermore, some multinucleate cells that are perhaps
'apoptosis-reluctant' undergo aberrant cell divisions into
several (more than 2) cells suggesting induction of aneu-
ploidy. At the molecular level, EM011 downregulated sur-
vivin, an important member of the inhibitor of apoptosis
(IAP) family of proteins. Abrogation of survivin by small-
interfering RNA led to an increased sensitivity of A549
cells towards EM011-induced cell death. These results sug-
gest the potential usefulness of EM011 in the manage-






sized as described earlier [13,19]. Sulforhodamine B
(SRB), 4-6-diamidino-2-phenylindole (DAPI), propidium
iodide (PI), RNase, bovine serum albumin (BSA), and the
mouse monoclonal antibody against α-tubulin were from
Sigma-Aldrich (St. Louis, MO, US). Antibodies against
caspase-3, cleaved PARP, Bcl2, BAX were obtained from
Cell Signaling (Beverly, MA). BubR1 was purchased from
BD Biosciences, PharMingen. Horseradish peroxidase-
conjugated anti-rabbit and anti-mouse secondary anti-
bodies were purchased from Sigma. Fluorescein-conju-Page 2 of 12
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ImmunoResearch, Inc. (West Grove, PA).
Cell lines and plasmids
Human lung cancer cells (H322 M, H266, H266B, H23,
H460, HOP-92, HOP-62, H1299, A549, H522, H157,
and H1792) were obtained from Dr. Wei Zhou's labora-
tory, Winship Cancer Institute, Emory University. All cells
were maintained in RPMI-1640 media supplemented
with 10% fetal bovine serum (Invitrogen Carlsbad, CA)
and 1% antibiotics. The plasmid construct encoding sur-
vivin and survivin siRNA plasmid were from Dr. Lily Yang,
Winship Cancer Institute, Emory University. The plasmid
vector with survivin siRNA sequence 5'-GGCTGGCT-
TCATCCACTGCCC-3' was generated by cloning the syn-
thesized oligonucleotide into pSilencer 2.1-U6Neo
plasmid (Ambion Inc., Austin, TX). Control pSilencer 2.1-
U6 Neo plasmid vector containing a scrambled siRNA
sequence, 5'-ACTACCGTTGTTATAGGTGT-3', was
obtained from Ambion Inc. The survivin plasmid contruct
was cloned into the pcDNA3 vector and pcDNA3 vector
alone served as control. All transfections were done using
Lipofectamine 2000 following the manufacturers' instruc-
tions.
In vitro cell proliferation assay
Lung cancer cells were seeded in 96-well plates at a density
of 5 × 103 cells/well followed by next day treatment with
increasing gradient concentrations of EM011 ranging
from 10 nm to 100 mM. After 48 hrs of drug treatment,
cells were fixed with 50% trichloroacetic acid and stained
with 0.4% sulforhodamine B (SRB) dissolved in 1% acetic
acid. Cells were then washed with 1% acetic acid to
remove the unbound dye. Essentially, the SRB assay meas-
ures cell density by quantitating colored SRB bound to cel-
lular proteins fixed to the plates by tricholoroacetate. The
protein-bound dye was extracted with 10 mM Tris-base to
determine the absorbance at 564 nm wavelength [20,21].
The percentage of cell survival as a function of drug con-
centration was then plotted to determine IC50 values
(drug concentration needed to prevent cell proliferation
by 50%).
Cell-cycle analysis
A549 cells were seeded in culture dishes and grown until
~70% confluence. The medium was then replaced with
new medium containing either vehicle (0.01% DMSO) or
25 μM EM011 for 6, 12, 18, 24, 36 and 48 hrs. After the
incubation period, cells were centrifuged, washed twice
with ice-cold PBS, and fixed in 70% ethanol. Tubes con-
taining the cell pellets were stored at 4°C for at least 24
hrs. Cells were then centrifuged at 100 × g for 10 minutes,
and the supernatant was discarded. Pellets were washed
twice with PBS and stained with PI in the presence of
RNase A for 45 minutes in dark. Samples were analyzed
on a FACSCalibur flow-cytometer (Beckman Coulter, Inc.,
Fullerton, CA).
Quantitation of mitotic cells by MPM-2 staining
A549 cells were collected and fixed with 70% ethanol.
Cells were treated with the blocking solution (PBS con-
taining 1% Triton X-100 and 1% BSA) for 1 hr, followed
by incubation with MPM-2 mouse monoclonal antibody
(Upstate Biotechnology, Lake Placid, NY) in blocking
solution for 1 hr. Cells were then incubated with Alexa
488-conjugated anti-mouse secondary antibody followed
by PI for DNA staining, and were read flow-cytometri-
cally.
Immunofluorescence confocal microscopy
A549 cells were grown on poly(L-lysine)-coated glass cov-
erslips for immunofluorescence microscopy as described
previously [13,15]. After treatment, cells were fixed with
cold (-20°C) methanol for 5 minutes and blocked by
incubating with 2% BSA/PBS at 37°C for 1 hr. A mouse
monoclonal antibody against α-tubulin (DM1A, Sigma)
was diluted 1:500 in 2% BSA/PBS and incubated with the
coverslips for 2 hrs at 37°C. Cells were then washed with
2% BSA/PBS for 10 minutes at room temperature before
incubating with a 1:200 dilution of a FITC-labeled goat
anti-mouse IgG antibody (Jackson ImmunoResearch,
Inc., West Grove, PA) at 37°C for 1 hr. Coverslips were
then rinsed with 2% BSA/PBS for 10 minutes and incu-
bated with PI (0.5 μg/mL) for 15 minutes at room temper-
ature before they were mounted with Aquamount (Lerner
Laboratories, Pittsburgh, PA) containing 0.01% 1,4-dia-
zobicyclo(2,2,2)octane (Sigma). Cells were examined
using confocal microscopy for microtubule and nuclear
morphology using a 63× objective (numerical aperture,
1.4).
Western blot analysis
Proteins were resolved by polyacrylamide gel-electro-
phoresis and transferred onto polyvinylidene difluoride
membranes (Millipore). Membranes were blocked in Tris-
buffered saline containing 0.2% Tween-20 and 5% fat-
free dry milk and incubated first with primary antibodies
and then with horseradish peroxidase-conjugated second-
ary antibodies. Specific proteins were visualized with
enhanced chemiluminescence detection reagent accord-
ing to the manufacturer's instructions (Pierce Biotechnol-
ogy).
Terminal deoxynucleotidyl-transferase-mediated dUTP 
nick-end labeling (TUNEL) assay for apoptosis
DNA strand breaks were identified using the TUNEL assay
as described [15]. Briefly, A549 cells treated with 25 μM
EM011 for 72 hrs were washed with ice-cold PBS, fixed in
1% paraformaldehyde, and 3'-DNA ends were detectedPage 3 of 12
(page number not for citation purposes)
Molecular Cancer 2009, 8:93 http://www.molecular-cancer.com/content/8/1/93using the APO-BrdU TUNEL Assay Kit (Molecular Probes,
Eugene, OR).
Determination of caspase-3 activity
106 cells were incubated with 25 μM EM011 for 0, 12, 24,
48 and 72 hrs. Caspase-3 activity was measured by cleav-
age of the small synthetic substrate Z-DEVD-aminoluci-
ferin (CaspaseGloTM 3/7 Assay System Kit, Promega,
Madison, WI) that becomes luminogenic upon cleavage.
The luminescent signal, which is directly proportional to
the amount of caspase-3 activity, was measured in a lumi-
nescence plate reader.
Results and Discussion
EM011 inhibits growth of a wide array of lung cancer cells
Noscapinoids represent a new generation of anticancer
agents that modulate microtubule dynamics but do not
significantly alter the total polymer mass of tubulin. Ear-
lier reports have shown that EM011, a brominated
noscapine analog, has potent antiproliferative and proap-
optotic activity in hormone-refractory breast cancer and
drug-resistant lymphoma models [14,15,17]. To evaluate
the efficacy of EM011 in lung cancer cells, we first exam-
ined the ability of EM011 to inhibit cellular proliferation
in a comprehensive panel of lung cancer cells with varia-
ble but well-characterized genotypes. The panel included
H322 M, H266, H266B, H23, H460, HOP-92, HOP-62,
H1299, A549, H522, H157, and H1792 lung cancer cells.
These 12 different lung cancer cell lines were treated with
gradient concentrations of EM011 and the extent of cell
proliferation was measured by the SRB assay, which is
based on the stoichiometric binding of SRB dye to all cel-
lular protein components [21]. As shown in Figure 1A,
EM011 effectively suppressed cellular proliferation of
lung cancer cells. The non-small cell lung cancer cell lines
included in the study had well-characterized p53 status,
namely, wild type (represented by H226, H460, A549),
null (such as H1299) and mutant (H322 M, H23, H522,
H157, H1792). Although the parent molecule, noscapine,
has been previously shown to induce a p53-dependent
apoptosis in colon cancer cells [22], these data show that
the half-maximal growth inhibitory concentrations of
EM011 did not correlate with the p53 status in lung cancer
cells. For example, H1299 that lacks endogenous p53
showed similar sensitivity as A549 (wild type p53) or
H522 (mutant p53) cells. The IC50 values for most lung
cancer lines studied were in the range of 4-10 μM. The rel-
atively less-sensitive lung cancer cells included HOP-92
(IC50 = ~12.5 μM), HOP-62 (IC50 = ~19.5 μM), H460
(IC50 = ~28 μM) and H1792 (IC50 = ~50 μM). Since the
A549 human epithelial cell line is widely-accepted as a
standardized experimental model with biological proper-
ties of alveolar epithelial type II cells, we chose these cells
to conduct further studies to gain insights into cellular
and molecular mechanisms of EM011 action. Phase-con-
trast microscopic analysis of cell morphology showed that
while vehicle-treated A549 cells proliferated normally,
EM011 treatment impaired their proliferation capacity
(Figure 1B). Cells first appeared rounded-up (24 hrs treat-
ment) followed by a fragmented morphology (72 hrs
treatment) (Figure 1B).
EM011 transiently blocks cell-cycle progression in the G2/
M phase
To investigate the precise mechanism responsible for
EM011-mediated antiproliferative effects, we examined
the cell-cycle distribution profile of EM011-treated A549
lung cancer cells over time. A flow-cytometric assay using
EM011 suppresses proliferation of human lung cancer cellsFigure 1
EM011 suppresses proliferation of human lung cancer cells. A. A panel of lung cancer cells ((H322 M, H266, H266B, 
H23, H460, HOP-92, HOP-62, H1299, A549, H522, H157, and H1792) were treated with gradient concentrations of EM011 
for 72 hrs and the IC50 values were evaluated by the sulforhodamine B (SRB) in vitro cell proliferation assay. The values and 
error bars shown in the graph represent average and standard deviations, respectively, of three independent experiments (p < 
0.05). B. Phase-contrast images (10×) of A549 cells treated with 25 μM EM011 for 0, 24, 48 and 72 hrs.Page 4 of 12
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lized to monitor cell-cycle progression on the basis of sta-
tus of DNA amounts. Figure 2A shows the time-
dependent effects of EM011 on cell-cycle profile of A549
cells in a three-dimensional representation. The x-axis
shows amount of DNA depicting different phases of the
cell-cycle. While 2N and 4N DNA complements represent
G0/G1 and G2/M cell populations respectively, S phase is
characterized by variable DNA (between 2N and 4N) and
sub-G1 population is usually indicative of degraded DNA,
a hallmark of apoptosis. The y-axis represents the number
of cells containing that amount of DNA and the z-axis
shows the time of drug-exposure. 0 hr depicts cell-cycle
profile of control cells. As we go along in time, EM011
treatment caused a significant inhibition of cell-cycle pro-
gression in A549 cells resulting in an accumulation of cells
in the G2/M phase compared to control cells (Figure 2B).
The G2/M population began to sharply rise as early as 6
hrs (~65%) post-treatment, achieved a maximum at 12
hrs (~80%) and was still about ~60% at 24 hrs of EM011
exposure (Figure 2B). This increased population of cells
with 4N DNA perhaps correlated with concomitant losses
from G0/G1 phases (Figure 2B). Following this, a disap-
pearance of the G2/M population and an emergence of a
EM011 perturbs cell-cycle progression of A549 lung cancer cellsFigure 2
EM011 perturbs cell-cycle progression of A549 lung cancer cells. Cells were harvested for analysis at the noted times, 
fixed and stained with propidium iodide, and analyzed by flow-cytometry using the Cell Quest Software. A. Effect of 25 μM 
EM011 on cell-cycle progression of A549 cells over time shown in a three-dimensional disposition. X-axis, intensity of propid-
ium iodide fluorescence, is indicative of the total DNA content of cells in various phases of the cell-cycle. Y-axis, number of 
cells detected for a given DNA content. Z-axis, time points (i.e., 0, 6, 12, 18, 24, 36, and 48 hrs). Representative results of 
three independent experiments. B. Quantitative graphical representation of the percentage of G2/M and sub-G1 cell popula-
tion. Points, average of three independent experiments; bars, SD (p < 0.05). C. A bar-graphical representation of relative per-
centage of cells in various cell-cycle phases over time of drug treatment. A549 cells achieved a maximal G2/M population at 12 
hrs (shown in green). D. Representative dot-plots depicting mitotic population at 0 and 12 hrs of drug-treatment as quantitated 
by MPM-2 and PI staining, flow-cytometrically. MPM-2, a well known phospho-serine/threonine antibody is recognized for its 
versatility because it can detect several mitotic phospho-proteins that are phosphorylated either directly or indirectly by M-
phase-promoting factor (MPF) upon entry into mitosis. E is a bar-graphical representation highlighting the near inverse-corre-
lation between the mitotic and sub-G1 population of cells in A549 cells. The values and error bars shown in the graph repre-
sent the averages and standard deviation (SD), respectively, of three independent experiments; (p < 0.05).Page 5 of 12
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was observed beginning 24 hrs, indicative of apoptotic
cells (Figure 2B). The sub-G1 population at 36 hrs (~15%)
increased to ~32% at 48 hrs post-treatment. Figure 2C is a
bar-graphical representation that provides an overview of
the percent cell population in various cell-cycle phases
upon EM011 treatment over time. These results suggest
that EM011-treated A549 cells arrested in the G2/M phase
preceding cell death.
EM011 treatment selectively accumulates cells in mitosis 
and not G2 phase
Although the cell-cycle experiment using PI for DNA read-
out is extremely useful for an overview of the percent cell
population in various cell-cycle phases, it cannot dissect
out differences between G2 and M phases as both have 4N
DNA amounts. Thus, we next examined the specific cell-
cycle phase (G2 or M) in which the cells arrested upon
EM011 treatment using a mitosis-specific marker, MPM-2.
The MPM-2 positive (mitotic) population increased to
~48% (47.4 ± 2.3%) in 6 hrs and peaked to ~68% (67.6 ±
1.9%) at 12 hrs after which a decrease in the MPM-2 pop-
ulation was observed (Figure 2D). The MPM-2 positive
population was still as high as ~43% (43.2 ± 2.1%) at 24
hrs. However, the mitotic population declined sharply to
~4% (3.8 ± 0.5%) at 36 hrs (Figure 2E).
EM011 perturbs spindle architecture and interferes with 
bipolar spindle formation
We next visualized cellular microtubules and the spindle
apparatus that is composed of microtubules in the
absence and presence of EM011 to detect cellular events
that were perturbed by drug action (Figure 3). The nuclear
morphology of A549 cells was also examined over time of
treatment. Immunofluorescence confocal microscopy was
employed to examine drug effects-microtubules were
A. Confocal immunomicrographs of microtubules (green) and DNA (red) in vehicle (0.01% DMSO) treated A549 cells display-ing hallmarks of a typical cell divi i n process in a cell-cycle, in particular, interp as a), metaphase (b), early anaphase (c), late anaphase (d), telophase (e), and cytokinesis (f, g)Fi ure 3
A. Confocal immunomicrographs of microtubules (green) and DNA (red) in vehicle (0.01% DMSO) treated 
A549 cells displaying hallmarks of a typical cell division process in a cell-cycle, in particular, interphase (a), 
metaphase (b), early anaphase (c), late anaphase (d), telophase (e), and cytokinesis (f, g). B. In contrast, EM011 
treatment arrested A549 cells at mitosis, impaired bipolar spindle formation, induced mitotic slippage, aneuploidy and apopto-
sis. EM011 treatment did not affect the radial array network of microtubules until 6 hrs of exposure (0 hr, (a); 6 hrs (b)). Aber-
rantly arrested cells with multipolar spindles were seen at 12 hrs (c) and 24 hrs (d) post-treatment. Cells started to exit mitosis 
without cell division beginning at about 30 hrs post-treatment (e). Thereafter, at 36-40 hrs post-treatment, several aberrant 
phenotypes were observed suggesting variability in cellular fate upon drug treatment. Multinucleate cells with small fragments 
of DNA indicating apoptotic bodies suggested cell death from G1-like tetraploid state (f). Some cells showed signs of DNA 
fragmentation while in mitosis suggesting mitotic death (g, h). However, some cells were seen to undergo asymmetric chaotic 
cytokinesis with triple midbody (i) and perhaps, led to the generation of aneuploid cells (j, k). Occasionally, aberrant separation 
into more than two abnormal cells (even multinucleated) were seen (l, m). At 48 hrs of drug exposure, several fragmented 
DNA pieces and clusters of small apoptotic bodies were observed (n).Page 6 of 12
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DNA was stained red using PI. Figure 3A represents confo-
cal micrographs of A549 cells that were treated with vehi-
cle (0.01% DMSO). Interphase cells showed normal
radial arrays of microtubules (Figure 3A, a). The doubling
time of A549 cells was observed to be about 22-24 hrs.
The mitotic population, a small percentage (~6-10%) of
the total number of cells in a cell-cycle at any given time,
displayed hallmark features of a typical mitotic process.
Congression of chromosomes at the metaphase plate fol-
lowed by anaphase onset, a characteristic telophase and
cytokinesis were evident (Fig 3A, b-g). Although EM011-
treated cells at 0 and 6 hrs showed normal microtubule
arrays (Figure 3B a, b), mitotically-arrested cells were visi-
ble at 12 hrs post-treatment (Figure 3B, c) and continued
to accumulate until 24 hrs (Figure 3B, d). The arrested
cells did not show normal bipolar spindles, rather dis-
played aberrant multipolar spindles. Predominantly, the
number of spindle poles observed was 3 or 4 (Fig 3B, c, d).
The mitotic block triggered by the spindle assembly check-
point is not permanent, and cells can exit mitosis aber-
rantly by a process known as mitotic slippage (also known
as adaptation) [23]. At 30 hrs post-treatment, there was an
emergence of G1-like interphase cells that were multinu-
cleated. Most likely, these multinucleated cells resulted
from a mitotic exit, that is, cells slipped out of an abnor-
mal multipolar mitosis without cell division (Figure 3B,
e). Upon mitotic slippage, cells enter pseudo G1-like
interphase with tetraploid (4N) cells. We observed that
these multinucleate cells continued to accumulate until
36-40 hrs. At 40 hrs post-treatment, several phenotypes
were observed, perhaps arising from the variability in cel-
lular fates within the same cell line. This was in conform-
ity with recent reports that suggest the existence of a high
degree of inter- and intra- line variability in cellular
responses to chemotherapeutic drug treatment [24,25].
Multinucleated cells with small pieces of fragmented
DNA, reminiscent of apoptotic bodies, were also seen at
about 40 hrs post-treatment suggesting initiation of cell
death directly from the G1-like multinucleate state (Figure
3B, f). Perhaps, there was a small percentage of mitotic
cells that were disintegrating, suggesting death directly
from a prolonged mitotic arrest (Figure 3B, g, h). Interest-
ingly, at 40-48 hrs of drug exposure, some multinucleate
A549 cells (10-15%) were seen to pursue abnormal cyto-
kinesis with triple or quadruple midbodies (Figure 3B, i).
These aberrant cell divisions result into several (more than
two) cells that are usually aneuploid (Figure 3B, j, k).
Asymmetric distribution of cytoplasm and chromatin
material was observable showing separation into more
than two abnormal cells (even multinucleate) suggesting
high degree of aneuploidy caused by drug treatment (Fig-
ure 3B, l, m). Asymmetric cytokinesis following multipo-
lar mitosis generated three or more aneuploid daughter
cells that may perhaps be inviable. In addition, several
fragmented DNA pieces and clusters of small apoptotic
bodies were seen at 48 hrs post-treatment (Figure 3B, n).
EM011 treatment induced mitotic exit after the transient 
mitotic block
We next quantitated the cell population that slipped out
of mitosis without cytokinesis using dual color-flow
cytometry (MPM-2 and PI). There was a significant drop
in the percentage of MPM-2 positive cells from ~43% (44
± 3%) at 24 hrs to ~4% (4.2 ± 0.5%) at 36 hrs of EM011
treatment indicating that cells had slipped out of mitosis
(Figure 4A). After mitotic exit, this population of cells
then appears as the MPM-2 negative tetraploid (4N) pop-
A. Quantitative flow-cytometric representation of mitotic exit using two-color staining (MPM-2 and PI)Figure 4
A. Quantitative flow-cytometric representation of mitotic exit using two-color staining (MPM-2 and PI). Repre-
sentative dot-plot shows that the mitotic population plummets at 36 hrs of EM011 treatment and there is a substantial increase 
in the 4N G2 population suggesting mitotic exit. B. Representative confocal immunofluorescence images of microtubules 
(green) and DNA (red) showing a multipolar mitotic cell (left panel) and a mitotically-exited G1-like multinucleate cell (right 
panel).Page 7 of 12
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to ~50% (49.6 ± 3.2%) at 36 hrs (Figure 4A). These flow-
cytometric data correlated with confocal microscopic
observations, lending support to the fact that cells with
aberrant multipolar spindles stall transiently in mitosis,
followed by decondensation of chromatin material, and
an exit from mitotic phase. Since cells have failed to suc-
cessfully progress through mitosis to execute cytokinesis,
they have 4N DNA amounts and can be seen as huge
multinucleated cells. Figure 4B depicts representative cells
from both states, mitotically-arrested (left panel) and
pseudo G1-like multinucleate state (right panel).
EM011 treatment alters expression of cell-cycle and 
apoptosis regulatory molecules
EM011 activates spindle assembly checkpoint in A549 cells
Most antimitotics are known to activate the spindle
assembly checkpoint [23]. BubR1, a component of the
mitotic checkpoint is phosphorylated during spindle
checkpoint activation [26]. Immunoblotting data showed
that EM011 activated the mitotic checkpoint as detected
by phosphorylation of BubR1 at 24 hrs of drug treatment
(Figure 5A). Intriguingly, the BubR1 signal faded at 48 hrs
and reappeared at 72 hrs post-treatment (Figure 5A).
Probing with MPM-2 antibody, a mitosis-specific marker,
that recognizes phosphorylation of Ser/Thr-Pro epitopes,
also showed re-emergence of positive MPM-2 signals at 72
hrs post-treatment (Figure 5A). The BubR1 phosphoryla-
tion at 24 hrs indicated the initial activation of the spindle
assembly checkpoint that accompanied drug-induced
mitotic arrest. Since mitotic slippage occurs after pro-
longed mitotic arrest (beyond 24 hrs), it is reasonable to
speculate that the absence of MPM-2 signals indicates exit
from mitosis at 48 hrs. However, the absence of BubR1
signals at 48 hrs is intriguing because mitotic slippage
from aberrant mitosis usually takes place by overriding an
activated checkpoint [23,26]. Both microscopic and flow-
cytometric data show that A549 cells exited mitosis after a
prolonged mitotic arrest upon activation of the spindle
checkpoint. To investigate the re-emergence of BubR1 and
MPM-2 signals, A549 cells were drug-treated for 72 hrs,
stained using PI and MPM-2 followed by dual-color flow-
cytometric analyses (Figure 5B). An emergence of a MPM-
2 positive cell population (4.9 ± 0.6%) with 8N DNA
amounts suggested that a sub-population of 'mitotically
slipped-out' cells perhaps, continue the cell-cycle by enter-
ing another round of DNA replication and mitosis. Paral-
lel immunostaining experiments revealed that 72 hrs
drug-treated cells showed some highly multipolar chaotic
mitotic figures (Figure 5C, left) as well as excessively huge
G1-like multinucleated/multilobed cells (Figure 5C,
right). It is noteworthy that BubR1 and MPM-2 signals
EM011 induces mitotic arrest by the activation of the spindle checkpointFigure 5
EM011 induces mitotic arrest by the activation of the spindle checkpoint. A shows immunoblots for BubR1 and 
MPM-2. Uniform loading of lysates was confirmed by immunoblotting for actin. B. Cells were analyzed for mitotic population at 
72 hrs post-treatment using two-color flow cytometry. Representative dot-plot shows a clear 8N mitotic population (MPM-2 
positive population) suggesting that mitotically exited cells continue to progress in the cell-cycle and enter a second round of 
DNA replication and mitosis. C shows an abnormally massive mitotic cell at 72 hrs (left) and a significantly huge G1-like multi-
nucleate cell (right).Page 8 of 12
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Molecular Cancer 2009, 8:93 http://www.molecular-cancer.com/content/8/1/93reappear at 72 hrs and at this point of time, the cells are
much larger in size compared with the first mitosis which
is consistent with cell growth without cell division. We
speculate that the massive cells with excessively huge DNA
contents perhaps, eventually trigger apoptosis due to gen-
otoxic stress.
EM011 downregulates survivin expression in A549 cells
Survivin, an antiapoptotic member of the inhibitor of
apoptosis (IAP) family is known to block apoptosis by
inhibiting caspases and antagonizing mitochondria-
dependent apoptosis [27]. A decrease in survivin levels
plays an important role in human NSCLC and in agree-
ment with this notion; several studies have concluded that
there is a strong correlation between increased survivin
levels and progression of human lung cancer [28-30]. Sur-
vivin is expressed at high level in many types of cancers,
but not in normal tissues from the same organs [31]. We
thus asked if EM011 alters survivin levels as part of its
anti-proliferative and pro-apoptotic action. To this end,
the expression levels of survivin were examined upon
EM011 treatment over time. 25 μM EM011 caused a
decline in survivin levels as early as 24 hrs and signifi-
cantly low levels were seen at 72 hrs post treatment (Fig-
ure 6A). In contrast, H1792 cells with a high IC50 value
(~50 μM) for EM011, did not show change in survivin lev-
A. Immunoblot analysis of A549 cells treated with EM011 for 0, 24, 48 and 72 hrsFigure 6
A. Immunoblot analysis of A549 cells treated with EM011 for 0, 24, 48 and 72 hrs. After the indicated times, cells 
were lysed and total protein was extracted, separated by SDS-PAGE, electrotransferred onto polyvinylidene difluoride mem-
brane, and subjected to immunoblotting with the indicated primary antibodies followed by incubation with horseradish peroxi-
dase-conjugated secondary antibodies. β-actin was used as a loading control. B. Knock-down of survivin using survivin siRNA 
enhances the apoptotic response of A549 cells to EM011 treatment. A549 cells were transfected with a plasmid encoding sur-
vivin siRNA and were then subjected to EM011 exposure for 0, 24, 48 and 72 hrs. An empty vector control was used in the 
experiments. Panel B shows three-dimensional FACS profile of survivin siRNA-transfected (T) and empty vector transfected 
(EV) cells for 0, 24, 48 and 72 hrs. C. Western blot analysis of the expression of survivin and β-actin in A549 cells transfected 
with control or survivin siRNAs. D. Quantitation of the percent sub-G1 population for control siRNA and survivin siRNA 
transfected cells. Values represent averages and error bars show SD (*, p < 0.05). E. Overexpression of survivin renders A549 
cells resistant to EM011-induced apoptosis. A549 cells were transfected with a survivin encoding plasmid construct to ectopi-
cally overexpress survivin. Panel E shows cell-cycle profiles of survivin-transfected cells along with empty vector-transfected 
controls. F. Western blot analysis of the expression of survivin and β-actin in A549 cells transfected with control or survivin 
plasmid. G. Quantitation of the percent sub-G1 population for the survivin-transfected and empty vector-transfected controls. 
Values represent averages and error bars show SD (#, not significant; *, p < 0.05). H. Quantitation of the time-dependent 
increase in caspase-3 activity upon EM011 treatment. Cells were treated with 25 μM EM011 for 0, 24, 48, and 72 hrs, and cas-
pase-3 activity was analyzed using the luminogenic substrate Z-DEVD-aminoluciferin. The values and error bars shown in the 
graph represent the averages and standard deviations, respectively, of three independent experiments; (p < 0.05).Page 9 of 12
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suggesting that survivin may play a role in conferring
resistance to EM011-induced apoptosis.
Knock-down of endogenous survivin by survivin siRNA sensitizes 
A549 cells to EM011-induced apoptosis
If survivin is important to EM011-induced apoptosis,
knock-down of endogenous survivin expression should
render A549 cells to become more susceptible to EM011
treatment. Thus, to determine whether downregulation of
survivin contributes to EM011-induced apoptosis, we
used a plasmid construct encoding survivin specific siRNA
to selectively knock-down endogenous survivin in A549
cells. After the knock-down, cells were drug-treated for 24,
48 and 72 hrs. Downregulation of survivin sensitized
A549 cells to EM011-induced apoptosis, whereas control
siRNA had no effect. Figure 6B shows representative cell-
cycle profiles indicating that abrogation of survivin led to
an increased sensitivity of lung cancer cells towards apop-
tosis upon drug treatment. This is evident from the differ-
ences in percent sub-G1 populations in cells that were
EM011-treated for 48 or 72 hrs after survivin knock-down
(~40% at 48 hrs and ~57% at 72 hrs) versus cells sub-
jected to control siRNA transfections (~30% at 48 hrs and
~45% at 72 hrs) prior to EM011 exposure for the matched
time points (Figure 6D). Immunoblots showing knock-
down efficiency of survivin siRNA at 24 hrs post-transfec-
tion compared to survivin levels in cells treated with con-
trol siRNA for the same time are depicted in Figure 6C.
Overexpression of survivin renders A549 cells resistant to EM011-
induced apoptosis
To further confirm the role of survivin in EM011-induced
apoptosis, we overexpressed survivin in A549 cells using a
survivin encoding plasmid construct. Ectopic overexpres-
sion of survivin protected cells against EM011-induced
apoptosis, whereas, control plasmid (empty vector, EV)
had no effects. Figure 6E depicts cell-cycle profiles show-
ing in pairs, the control plasmid (EV) and survivin plas-
mid transfected (T) cells, which were drug-treated for 24,
48 and 72 hrs post-transfection. There was a reduction in
percent sub-G1 population in cells that were transfected
with the survivin plasmid (~27% at 48 hrs) compared to
when cells were transfected with a control plasmid con-
struct (~35% at 48 hrs). The protective effects of survivin
overexpression were also visible at 72 hrs of transfection
(~32% sub-G1 population) compared to control plasmid
(~50% sub-G1 population) (Figure 6G). However, among
the control and survivin plasmid transfected cells, differ-
ences in sub-G1 population at 24 hrs post drug-treatment
were not statistically significant. Immunoblots showing
ectopic overexpression efficiency of the survivin plasmid
at 24 hrs post-transfection compared to survivin levels in
cells treated with empty pcDNA3 vector are depicted in
Figure 6F.
EM011 decreases Bcl2/BAX ratio in A549 cells
It has been proposed that prolonged mitotic arrest stimu-
lates the phosphorylation of Bcl2, thereby resulting in its
inactivation [32-34]. Bcl2 in the unphosphorylated form
complexes with BAX, and thus its phosphorylation
releases BAX from the Bcl2-BAX complex [35-37].
Unbound BAX translocates from cytosol to the mitochon-
drial membrane to signal triggering of the downstream
apoptotic cascade, such as release of cytochrome c and
activation of executionery caspases [35-37]. EM011 acti-
vates mitochondrially-mediated intrinsic apoptotic path-
way in breast cancer and lymphoma cells [14,15,17]. To
examine the time-dependent effects of EM011 on Bcl2
proteins in A549 cells, we analyzed changes in the expres-
sion levels of proapoptotic BAX and antiapoptotic Bcl2.
EM011 induced mitotic arrest in A549 cells was accompa-
nied by the hyperphosphorylation of Bcl2 and there
occurred an increase of BAX protein levels in a time-
dependent manner (Figure 6A). This led to a decrease in
the antiapoptotic/proapoptotic (Bcl2/BAX) ratio as a
function of time of treatment (Figure 6A) suggesting
involvement of Bcl2 family members in EM011-induced
cell death.
EM011 causes activation of caspase-3 and cleavage of its 
downstream target, PARP
Upon cleavage by upstream proteases in an intracellular
cascade, the activation of caspase-3 is considered as a hall-
mark of the apoptotic process. The levels of cleaved active
subunits of executioner caspase-3 were evaluated by
immunoblotting cell lysates following EM011 treatment
for 0, 24, 48 and 72 hrs. EM011 caused a significant
increase in activated caspase-3 following 72 hrs of EM011
exposure (Figure 6A). To confirm the involvement of cas-
pase-3, the active form of the cysteine protease was mon-
itored using a small conserved modified peptide substrate
that becomes luminogenic upon cleavage. EM011 treat-
ment caused a time-dependent activation of caspase-3 in
A549 cells (Figure 6H). Next, we examined the activation-
mediated cleavage of caspase-3 substrate, poly(ADP-
ribose) polymerase (PARP), which is a reliable marker of
apoptosis. Utilizing their cysteine protease activity, cas-
pases separate N-terminal DNA-binding domain of PARP
from its C-terminal catalytic domain (89 kDa) [38]. A
time-dependent increase in cleaved PARP was observed
upon probing with a cleaved PARP specific antibody (Fig-
ure 6A). Overall, these results show activation of caspase-
3 and PARP cleavage suggesting that EM011 induced
apoptotic cell death in A549 cells.
EM011 triggers apoptosis as seen by an increase of TUNEL-positive 
cells
Figure 7A shows DAPI-stained micrographs with frag-
mented nuclei reminiscent of apoptotic bodies at 72 hrs
post-treatment, emphasizing the incidence of apoptosis.Page 10 of 12
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nuclei increased with the time of drug treatment (data not
shown). To further validate apoptosis, the increase in the
concentration of 3'-DNA ends due to fragmentation was
quantified using a flow-cytometry based TUNEL assay.
EM011-treated A549 cells showed ~44% TUNEL-positive
cells (Figure 7B) at 72 hrs of exposure compared to con-
trol cells, suggesting extensive DNA cleavage.
Conclusion
These data show that EM011 is anti-proliferative and pro-
apoptotic in lung cancer cells. The inhibition of cellular
proliferation is perhaps due to induction of a robust tran-
sient mitotic arrest in A549 cells. This is followed by an
abnormal exit of cells from mitosis without cytokinesis
into a pseudo G1-like multinucleate state. These abnor-
mally huge cells perhaps trigger activation of apoptotic
cell death program that is mitochondrially-driven and
executed through the activated caspase machinery by the
cleavage of downstream targets such as PARP. The A549
cell death program is also mediated through downregula-
tion of survivin, in that knock-down of survivin sensitized
cells to undergo apoptosis whereas overexpression of sur-
vivin reduced EM011-induced apoptosis. This study iden-
tifies the potential usefulness of EM011, a non-toxic
microtubule-modulating agent, in the management of
lung cancer.
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